Nonetheless, mice treated with adjuvant anti‐HSP90 therapy experienced a less aggressive relapse as measured by the reduced systemic impact (i.e., weight loss) of uncontrolled tumor growth in the brain (Fig 5J). Here, HSP90AA1 is linked to neoplasm.